ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $38.57 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $38.57, a 16.26% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $46.06, a 252.41% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $13.07, a 72.60% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $47.70, a 10.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $38.57 10-K · filed 2026-02-18 |
| 2024-12-31 | $46.06 10-K · filed 2025-02-19 |
| 2023-12-31 | $13.07 10-K · filed 2024-02-21 |
| 2022-12-31 | $47.70 10-K · filed 2023-02-17 |
| 2021-12-31 | $53.14 10-K · filed 2022-02-15 |
| 2020-12-31 | $58.51 10-K · filed 2022-02-15 |
| 2019-12-31 | $32.87 10-K · filed 2022-02-15 |
| 2018-12-31 | $36.21 10-K · filed 2021-02-12 |
| 2017-12-31 | $16.25 10-K · filed 2020-02-14 |
| 2016-12-31 | $21.21 10-K · filed 2019-02-20 |
| 2015-12-31 | $8.65 10-K · filed 2018-02-21 |
| 2014-12-31 | $2.14 10-K · filed 2017-02-17 |
| 2013-12-31 | $0.55 10-K · filed 2016-02-26 |
| 2012-12-31 | $0.31 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |